Rockwell Medical (RMTI) Q3 2024 earnings summary

Executive summary

• Achieved profitability on a cash flow and Adjusted EBITDA basis for the second consecutive quarter, with record quarterly concentrate product sales, gross profit, and gross margin in company history, driven by strong sales, operational improvements, and a special large order from the largest customer.

• Net sales for Q3 2024 increased 19% year-over-year to $28.3 million, with gross profit rising to $6.2 million and net income of $1.7 million, reflecting improved pricing, cost controls, and a special order.

• Entered a multi-million dollar international distribution agreement and expanded product offerings, including a convenience pack for the at-home dialysis market.

• Renewed and expanded supply agreements with key partners, supporting growth in both domestic and international markets.

• The company operates as the largest supplier of liquid bicarbonate concentrates and the second largest supplier of acid and dry bicarbonate concentrates for dialysis in the U.S.

Financial highlights

• Q3 2024 net sales reached $28.3 million, up 19% year-over-year; excluding deferred revenue, up 31%.

• Gross profit for Q3 2024 was $6.2 million, a 183% increase year-over-year; excluding deferred revenue, up 464%.

• Gross margin for Q3 2024 was 22%, up from 9% in Q3 2023; for the nine months ended September 30, 2024, gross margin was 18%.

• Q3 2024 net income was $1.7 million, compared to a net loss of $1.9 million in Q3 2023; nine-month net income was $0.3 million (vs. $6.9 million loss in 2023).

• Adjusted EBITDA for Q3 2024 was $2.8 million, compared to negative $1.2 million in Q3 2023; for nine months ended September 30, 2024, adjusted EBITDA was $3.8 million, up $9.7 million year-over-year excluding deferred revenue.

• Cash, cash equivalents, and investments at September 30, 2024, were $18.3 million, up from $11.9 million at June 30, 2024.

Outlook and guidance

• Q4 2024 revenue projected between $23 million and $25 million, with gross margin in line with previous quarters and continued profitability on an Adjusted EBITDA basis.

• 2024 guidance raised: net sales $98–101 million, gross profit $15–17 million, gross margin 16–18%, Adjusted EBITDA $4–5 million.

• 2025 expected to see a shift in customer mix, with a decline in net sales from the largest customer by $31–38 million, but profitability on an EBITDA basis is expected to be maintained.

• DaVita contract extended through 2025 with higher pricing but expected volume decline; net sales to DaVita in 2025 projected to decrease to $31–$37 million.

• Management believes current working capital is sufficient for at least the next twelve months and may raise additional capital via $4.5 million remaining under its ATM facility or other financing methods.